KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Finished Goods (2017 - 2025)

Historic Finished Goods for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $2.0 million.

  • Bionano Genomics' Finished Goods fell 7853.14% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 7853.14%. This contributed to the annual value of $4.2 million for FY2024, which is 5888.73% down from last year.
  • Per Bionano Genomics' latest filing, its Finished Goods stood at $2.0 million for Q3 2025, which was down 7853.14% from $3.3 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Finished Goods high stood at $19.8 million for Q2 2022, and its period low was $300000.0 during Q1 2021.
  • In the last 5 years, Bionano Genomics' Finished Goods had a median value of $9.1 million in 2024 and averaged $9.6 million.
  • In the last 5 years, Bionano Genomics' Finished Goods tumbled by 7963.34% in 2021 and then surged by 494300.0% in 2022.
  • Over the past 5 years, Bionano Genomics' Finished Goods (Quarter) stood at $6.1 million in 2021, then soared by 186.06% to $17.4 million in 2022, then crashed by 41.08% to $10.2 million in 2023, then crashed by 58.89% to $4.2 million in 2024, then crashed by 53.63% to $2.0 million in 2025.
  • Its Finished Goods stands at $2.0 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.3 million for Q1 2025.